Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
MT Osterholm, NS Kelley, A Sommer… - The Lancet infectious …, 2012 - thelancet.com
Background No published meta-analyses have assessed efficacy and effectiveness of
licensed influenza vaccines in the USA with sensitive and highly specific diagnostic tests to …
licensed influenza vaccines in the USA with sensitive and highly specific diagnostic tests to …
[HTML][HTML] MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia …
J Puig-Barberà, A Natividad-Sancho, J Calabuig-Pérez… - Vaccine, 2013 - Elsevier
Background Adjuvanted influenza vaccines offer greater and broader immunogenicity to
older adults than conventional vaccines. Studies assessing the comparative effectiveness of …
older adults than conventional vaccines. Studies assessing the comparative effectiveness of …
A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly …
C Hatz, F von Sonnenburg, D Casula, M Lattanzi… - Vaccine, 2012 - Elsevier
BACKGROUND: Vaccines against pandemic A/H1N1 influenza are required to protect the
entire population. This dose range study aimed to identify priming antigen and adjuvant …
entire population. This dose range study aimed to identify priming antigen and adjuvant …
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre …
J Beran, H Reynales, A Poder, YY Charles… - The Lancet Infectious …, 2021 - thelancet.com
Background The absolute degree of protection from influenza vaccines in older adults has
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59 …
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59 …
Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults
JY Song, HJ Cheong, YB Seo, IS Kim… - Clinical and Vaccine …, 2012 - Am Soc Microbiol
Since the first reports of the A/H1N1 virus in April 2009, the pandemic influenza virus spread
globally and circulated for a long time. The primary method for the control of influenza is …
globally and circulated for a long time. The primary method for the control of influenza is …
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: Results from a dose-finding clinical trial in older adults
G Della Cioppa, U Nicolay, K Lindert… - Human vaccines & …, 2012 - Taylor & Francis
Background: MF59-adjuvanted influenza vaccines have superior immunogenicity in older
adults compared with non-adjuvanted vaccines. We assessed whether changing formulation …
adults compared with non-adjuvanted vaccines. We assessed whether changing formulation …
Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant
T Vesikari, M Pellegrini, A Karvonen… - The Pediatric …, 2009 - journals.lww.com
Background: Children have high morbidity and hospitalization rates from seasonal
influenza. Meta-analyses suggest that conventional inactivated influenza vaccines are of low …
influenza. Meta-analyses suggest that conventional inactivated influenza vaccines are of low …
Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: a systematic review and meta-analysis
JK Breteler, JS Tam, M Jit, JCF Ket, MR De Boer - Vaccine, 2013 - Elsevier
Purpose Influenza vaccines have been recommended for populations at risk for severe
infection in low and middle income countries (LMICs) although knowledge of the evidence …
infection in low and middle income countries (LMICs) although knowledge of the evidence …
Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese …
H Fukase, H Furuie, Y Yasuda, R Komatsu… - Vaccine, 2012 - Elsevier
INTRODUCTION: Effective vaccination strategies are required to combat future influenza
pandemics. Here we report the results of three independent clinical trials performed in …
pandemics. Here we report the results of three independent clinical trials performed in …
Point-of-use mixing of influenza H5N1 vaccine and MF59 adjuvant for pandemic vaccination preparedness: antibody responses and safety. A phase 1 clinical trial
MJ Mulligan, DI Bernstein, S Frey… - Open forum …, 2014 - academic.oup.com
Abstract Background. Avian influenza A/H5N1 has threatened human health for nearly 2
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …